By constantly expanding the knowledge and combining new ideas with over 55 years of experience, Fidia wants to become the partner of choice in the segment of hyaluronic acid-based treatments for osteoarthritis. In fact, this is the area that has traditionally been of great importance along the whole history of the company.

Fidia has an extensive patent portfolio (over 1,300 international patents), with nearly 1,100 patents on Hyaluronic Acid, its derivatives, pharmaceutical compositions and formulations, as well as various industrial processes which allow us to develop innovative therapeutic solutions based on Hyaluronic Acid.

There is something that makes Fidia stand out from the rest: Hyaluronic Acid production processes, that involve different sources using internally developed and patented methods for the production of Hyaluronic Acids with different molecular weights and physico-chemical properties.

Fidia is constantly striving to discover new options for developing promising new products. This is an important prerequisite for the successful future of our company.

  • - Over 55 years of experience with hyaluronic acid
  • - Over 1,100 international patents
  • - Innovative therapeutic solutions

Farmaceutici S.p.A.

Find out our Corporate Website:

Go to the website

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Russia product portfolio focalizes primarily on joint healthcare.

Fidia Pharma Russia is focused on providing consumers with innovative products that offer quality, safety and performance.